, /PRNewswire/ -- Avirmax CMC, a leader in the innovation and manufacture of adeno-associated virus (AAV) vector-mediated biotherapeutics, announces the successful delivery to its first client with Good Manufacturing Practice (GMP) lots of AAV vector product trial use. This milestone marks a significant achievement in Avirmax CMC's mission to provide high-quality gene therapy solutions. The GMP-compliant AAV vectors were produced using Avirmax's state-of-the-art VSaf rBV-Sf9 technology platform, which ensures high titers at extremely low empty capsid ratio, and enhanced expression of the gene of interest (GOI).

The delivered vector product will play a crucial role in the upcoming clinical trial, aimed at treating ocular diseases. "Our team at Avirmax CMC is thrilled to have reached this pivotal point in our journey. Delivering to our first customer with GMP lot of AAV vector product underscores our commitment to excellence and our capability to meet stringent regulatory standards and customer's satisfaction," said Dr.

Shengjiang Shawn Liu, CEO & CSO of Avirmax CMC Inc. "We are dedicated to advancing gene therapy development for partners and making these innovative treatments accessible to patients in need." The GMP AAV product lots were produced, tested and packaged at Avirmax CMC's cutting-edge facility in the , the heart of , which is equipped with single use technologies for scalable and robust manufacturing processes.

The production process ensures that the vector product.